Welcome to our dedicated page for Drugs Made In America Acquisition II news (Ticker: DMIIU), a resource for investors and traders seeking the latest updates and insights on Drugs Made In America Acquisition II stock.
Drugs Made In America Acquisition II Corp. is a blank-check company whose updates center on SPAC security structure, shareholder voting matters and capital-structure disclosures. News for DMIIU generally relates to its units, ordinary shares and rights, along with governance actions and other developments typical of a Nasdaq-listed SPAC pursuing a business combination.
Drugs Made In America Acquisition II Corp (NASDAQ: DMIIU) announced that, commencing December 3, 2025, holders of units sold in the Company’s September 26, 2025 IPO may elect to separately trade the ordinary shares and rights included in each unit on the Nasdaq Global Market.
Each unit contains one ordinary share and one right to receive 1/10 of an ordinary share upon consummation of an initial business combination. Separated ordinary shares will trade as DMII and separated rights as DMIIR; units remaining intact will continue to trade as DMIIU. Holders must have brokers contact Continental Stock Transfer & Trust Company, the transfer agent, to effect separation. Cantor Fitzgerald acted as sole book-running manager for the offering.
Drugs Made In America Acquisition II Corp. (Nasdaq: DMIIU) has successfully completed its initial public offering, raising $500 million in gross proceeds through the sale of 50 million units at $10.00 per unit. Each unit comprises one ordinary share and one right to receive one-tenth of an ordinary share upon business combination completion.
The company also conducted a concurrent private placement of 1.2 million units at $10.00 per unit, generating additional proceeds of $12 million. The underwriters have a 45-day option to purchase up to 7.5 million additional units to cover over-allotments. $500 million has been deposited into a trust account from the combined proceeds.
Drugs Made In America Acquisition II Corp. (Nasdaq: DMIIU) has announced the pricing of its initial public offering (IPO) of 50,000,000 units at $10.00 per unit, totaling $500 million. Each unit includes one ordinary share and one right to receive one-tenth of an ordinary share upon business combination completion.
The units will trade on Nasdaq under "DMIIU" starting September 25, 2025, with ordinary shares and rights later trading separately under "DMII" and "DMIIR". Underwriters have a 45-day option to purchase up to 7.5 million additional units for over-allotments. Cantor Fitzgerald & Co. serves as the sole book-running manager, with closing expected September 26, 2025.